Synflorix

Synflorix Dosage/Direction for Use

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
Official recommendations should be taken into account when immunising with Synflorix.
Infants from 6 weeks to 6 months of age: 3-dose primary series: An immunization series of 4 doses, each of 0.5 ml, is recommended to ensure optimal protection: 3 primary doses with an interval of at least 1 month between doses and a booster dose at least 6 months after the last primary dose. The first dose may be given as early as 6 weeks of age and the booster dose from the age of 9 months onwards (see Pharmacology: Pharmacodynamics under Actions).
2-dose primary series: Alternatively, when Synflorix is given as part of a routine infant immunization programme, a series of 3 doses, each of 0.5 ml, may be given: 2 primary doses given 2 months apart and a booster dose at least 6 months after the last primary dose. The first dose may be given as early as 6 weeks of age and the booster dose from the age of 9 months onwards (see Pharmacology: Pharmacodynamics under Actions).
Preterm infants born after at least 27 weeks of gestational age: An immunization series of 4 doses, each of 0.5 ml, is recommended: 3 primary doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses with a booster dose at least 6 months after the last primary dose (see Pharmacology: Pharmacodynamics under Actions).
Previously unvaccinated older infants and children: 7-11 months of age: 2 doses of 0.5 ml with an interval of at least 1 month between doses. A third dose is recommended in the second year of life with an interval of at least 2 months.
12 months - 5 years of age: 2 doses of 0.5 ml with an interval of at least 2 months between doses.
Special populations: In individuals who have underlying conditions predisposing them to invasive pneumococcal disease (such as Human Immunodeficiency Virus (HIV) infection, sickle cell disease (SCD), or splenic dysfunction), Synflorix may be given according to the previously mentioned schedules, except that a 3-dose schedule should be given as primary vaccination in infants starting vaccination from 6 weeks to 6 months of age (see Precautions and Pharmacology: Pharmacodynamics under Actions).
It is recommended that subjects who receive a first dose of Synflorix complete the full vaccination course with Synflorix.
The vaccine should be given by intramuscular injection. The preferred sites are anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in